Fulgent Genetics (FLGT) Cash & Equivalents (2015 - 2026)

Fulgent Genetics (FLGT) has 12 years of Cash & Equivalents data on file, last reported at $23.4 million in Q1 2026.

• Quarterly Cash & Equivalents fell 65.22% year-over-year to $23.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $23.4 million (down 65.22% YoY) and the FY2025 annual result came in at $50.2 million, down 8.98% from the prior year.
• Cash & Equivalents retreated to $23.4 million in Q1 2026 per FLGT's latest filing, from $50.2 million in the prior quarter.
• The five-year high for Cash & Equivalents was $353.1 million in Q1 2022, with the low at $23.4 million in Q1 2026.
• Average Cash & Equivalents over 5 years is $84.3 million, with a median of $66.2 million recorded in 2023.
• Year-over-year, Cash & Equivalents surged 703.65% in 2022 and plunged 81.26% in 2023.
• Fulgent Genetics' Cash & Equivalents stood at $79.5 million in 2022, then grew by 22.6% to $97.5 million in 2023, then slumped by 43.43% to $55.1 million in 2024, then decreased by 8.98% to $50.2 million in 2025, then plunged by 53.38% to $23.4 million in 2026.
• Business Quant data shows FLGT's Cash & Equivalents at $23.4 million in Q1 2026, $50.2 million in Q4 2025, and $117.6 million in Q3 2025.